Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

EMA could follow FDA’s Xeljanz blood clot warning

EMA could follow FDA’s Xeljanz blood clot warning

It is the first JAK inhibitor drug on the market for imflammatory conditions, offering a more convenient oral formulation compared to injectable rivals. ... The new safety signals could also cast a cloud over the entire JAK inhibitor class at risk,

Latest news

More from news
Approximately 4 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch January 2018

    Acquisition company -  remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302,

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during September 2013 Pharma deals during September 2013

    cancer, and AT13387, a second generation HSP90 inhibitor for the treatment of prostate and lung cancers. ... antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

  • Pharma deals during October 2012 Pharma deals during October 2012

    Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... 60. ‡‡Ethical Oncology Science / Servier.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics